Serum Lipidomics Profiling to Identify Biomarkers for Non-Small Cell Lung Cancer

Table 4

Statistical analysis of differential lipids to distinguish early-stage NSCLC from LBD group.

Peak	Lipid	Polarity	p value	VIP value	Fold Change
1	PC(22:5/10:0)	POS	<0.001	1.67	1.73
2	PE(P-18:0/18:2)	POS	<0.001	2.71	1.68
3	PC(2:0/17:1)	POS	0.003	1.63	1.58
4	PC(2:0/17:2)	POS	0.003	1.54	1.56
5	PC(3:0/18:4)	POS	0.006	1.70	1.56
6	TG(12:0/18:1/16:1)	POS	<0.001	2.59	1.55
7	PI(16:0/16:1)	NEG	0.033	1.22	1.57
8	PC(18:4/3:0)	NEG	0.008	1.66	1.50

NSCLC, non-small cell lung cancer; LBD, lung benign disease.